ABSTRACT
Spinal muscular atrophy (SMA) is a neurodegenerative disease characterized by a varying degree of severity that correlates with the reduction of SMN protein levels. Motor neuron degeneration and skeletal muscle atrophy are hallmarks of SMA, but it is unknown whether other mechanisms contribute to the spectrum of clinical phenotypes. Here, through a combination of physiological and morphological studies in mouse models and SMA patients, we identify dysfunction and loss of proprioceptive sensory synapses as key signatures of SMA pathology. We demonstrate that SMA patients exhibit impaired proprioception, and their proprioceptive sensory synapses are dysfunctional as measured by the neurophysiological test of the Hoffmann reflex (H-reflex). We further show that loss of excitatory afferent synapses and altered potassium channel expression in SMA motor neurons are conserved pathogenic events found in both severely affected patients and mouse models. Lastly, we report that improved motor function and fatigability in ambulatory SMA patients and mouse models treated with SMN-inducing drugs correlate with increased function of sensory-motor circuits that can be accurately captured by the H-reflex assay. Thus, sensory synaptic dysfunction is a clinically relevant event in SMA, and the H-reflex is a suitable assay to monitor disease progression and treatment efficacy of motor circuit pathology.
One-sentence summary Sensory-motor circuit dysfunction involving impairment of proprioceptive synapses on motor neurons is a conserved pathogenic event and therapeutic target across animal models and humans with spinal muscular atrophy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded and supported by R01 NS078375 (GZM), R01 NS125362 (GZM), R01 AA027079 (GZM), The SMA Foundation (GZM), Project ALS (GZM); German Research Foundation grants SI1969/2 1 (CMS), SI1969/3 1 (CMS), SMA Europe (CMS), CMS was also the recipient of Young Investigator award by ROCHE; R01 NS102451 (LP), R01 NS114218 (LP), R01 NS116400 (LP); SMA Foundation (CJS), R35 NS122306 (NINDS to CJS); K12HD001399 (PK), American SIDS Institute (PK), Raynor Cerebellum Project (PK); K01 HD084690 (JM) and Cure SMA (CU18 2886; JM), Grant from F. Hoffmann La Roche (MC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Columbia University Irving Medical Center Institutional Review Board (AAAE8252) approved the work. The experimental protocol for this joint position test was approved by the University of Pittsburgh Institutional Review Board (protocol STUDY21080158).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
